RTTNews | May 3, 2021 08:13AM EDT

08:12 Monday, May 3, 2021 (RTTNews.com) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), said it will present new data from the 3-year open-label extension study of AUSTEDO Tablets that studied patients with tardive dyskinesia. The company noted that the new data includes three abstracts that examine the long-term safety, quality of life and patient-centered outcome measures of patients living with tardive dyskinesia who were treated with AUSTEDO up to 145 weeks following two pivotal 12-week studies.

AUSTEDO is indicated for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia in adults.

Read the original article on RTTNews ( https://www.rttnews.com/3190728/teva-pharma-to-present-data-from-3-yr-open-label-extension-study-of-austedo-tablets.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved